Lamictal Launched As Monotherapy In UK
Wellcome has launched its anticonvulsant drug Lamictal (lamotrigine) as a monotherapy for epilepsy in the UK. This is the first drug to be launched for the single-agent treatment of epilepsy in the UK for 20 years. Wellcome notes that Lamictal has fewer side effects than older antiepileptic drugs due to its more selective mode of action.
Lamictal has also been approved as a monotherapy in South Africa, where it is already marketed, and the Netherlands, where it is due for launch shortly. Wellcome has submissions under consideration in 16 other countries for the use of lamotrigine as a monotherapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze